FF-10832

Phase 2Small molecule

FFujifilm Pharmaceuticals U.S.A., Inc.

FF-10832 is one of 76 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Solid TumorPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 3

34 2

Decadron

AAspen Global Incorporated

Phase 3

10 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

FF-10832

FFujifilm Pharmaceuticals U.S.A., Inc.

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Solid Tumor

NCT03440450

Q4 2029

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05318573

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Active, not recruiting·FFujifilm Pharmaceuticals U.S.A., Inc.·Phase 2·NCT05318573·120 enrolled

Solid Tumor1 trial

A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors

Active, not recruiting·FFujifilm Pharmaceuticals U.S.A., Inc.·Phase 1·NCT03440450·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FF-10832. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FF-10832 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FF-10832. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujifilm Pharmaceuticals U.S.A., Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFujifilm Pharmaceuticals U.S.A., Inc.

FF-10832

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News